Celgene said it will discontinue a Phase III study of its blood cancer treatment Revlimid as a first-line treatment in elderly patients with B-cell chronic lymphocytic leukemia after it noticed more deaths in patients treated with Revlimid compared with patients taking chlorambucil. The FDA put the study on clinical hold last week. Celgene said it will examine data from the trial to determine whether the imbalance is due to factors such as age or comorbidities.

Related Summaries